Sotera Health stock carries Barclays Buy rating with USD 22 target
Published on 10/08/2026 at 02:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sotera Health Company (ISIN US83601L1026) was last at USD 18.13 on Nasdaq on October 7, 2026, down 0.68 percent from the prior close. The latest analyst action came from Barclays, which maintained a Buy rating and set a USD 22.00 price target on October 7, according to Markets Insider.
Barclays keeps USD 22 target
The Barclays target lies 21.3 percent above the October 7 Nasdaq price. The analyst action gives the stock a fresh valuation reference after Sotera Health delivered its second-quarter results and raised its full-year outlook.
RBC Capital also maintained a Buy rating with a USD 24.00 target on October 6, according to Markets Insider. The RBC target is 32.4 percent above the same Nasdaq price, although that report describes a maintained rating rather than a new upgrade.
Revenue grows 9.2 percent
Sotera Health reported Q2 2026 net revenue of USD 321.38 million, up 9.2 percent from USD 294.34 million in Q2 2025, according to the companys investor-relations update dated August 6, 2026, available through Sotera Health.
The same release reported Q2 2026 net income of USD 54 million, compared with USD 8 million in Q2 2025, while diluted earnings per share rose to USD 0.19 from USD 0.03. Operating cash flow reached USD 88.5 million in Q2 2026, according to the standardized quarterly financial data.
Consensus points to USD 21.50
MarketBeat reported on September 25, 2026, that 11 analysts covering Sotera Health held a Moderate Buy consensus, with eight Buy ratings and three Hold ratings. The average 12-month target was USD 21.50, or 18.6 percent above the October 7 Nasdaq price, according to MarketBeat.
The companys services span contract sterilization, laboratory testing and advisory work for healthcare customers. That recurring service mix sits alongside heavy investment, with 2026 capital spending guided at USD 200 million to USD 225 million in a September 9, 2026 conference presentation summarized by Investing.com.
Q3 results set for November 3
Sotera Health is scheduled to report Q3 2026 results on November 3, 2026, before the market opens, with a conference call at 9:00 a.m. ET, according to MarketBeat. The scheduled report is the next concrete checkpoint for testing whether the Q2 revenue pace and raised outlook are carrying into the second half.
Stock stays below yearly high
Sotera Health was last at USD 18.13 on Nasdaq on October 7, 2026, with a 52-week range of USD 13.09 to USD 19.85 and market capitalization of USD 5.2 billion. Trading volume stood at 62,380 shares at the quoted 9:50 a.m. EDT update.
Sotera Health stock facts
- Company: Sotera Health Company
- ISIN: US83601L1026
- Ticker: SHC
- Trading venue: Nasdaq
- Price (as of October 7, 2026, 9:50 a.m. EDT): USD 18.13
- Market capitalization: USD 5.2 billion (as of October 7, 2026)
- 52-week range: USD 13.09-19.85 (as of October 7, 2026)
- Sector / Industry: Healthcare / Medical diagnostics and research
Upcoming dates for Sotera Health stock
- November 3, 2026: Q3 2026 results and conference call
